(2) for what reason his Department bid for a stockpile size of 54,000 courses of A/H5N1 vaccine, as referred to in paragraph 8 of the Defence Medical Services Department’s policy letter of 20 January 2006, entitled “The use of influenza vaccines and anti-virals in the event of an influenza pandemic” by the Defence Medical Services, reference DMSD/13/1/4; and if he will make a statement.
The Department's stockpile was calculated on the need to have sufficient courses to vaccinate those personnel engaged on, or preparing for, deployed operations and other essential tasks, plus a specific allocation for Defence Medical Services (DMS) healthcare personnel. Around 10 per cent. has been allocated for vaccination of DMS personnel, and the remaining 90 per cent. for other members of the armed forces.
Around 17,500 courses of influenza anti-virals earmarked for future operational demands are held by the Defence Storage and Distribution Agency (DSDA) on behalf of the Defence Equipment and Support. PJHQ will authorise distribution of the appropriate quantities to operational theatres as required.
In accordance with Defence Medical Services guidance, 10 anti-viral courses are held in Role 2(Enhanced) field hospitals overseas; five courses in the unit at Basra in Iraq and five in the one at Camp Bastion in Afghanistan. The majority of MOD’s anti-viral stocks are held by the Defence Equipment and Support in the UK, from whence they can be transported at short notice to any overseas location as required.